CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 2,539 enrolled
Drug / intervention
Aspirin +1 moredrug
Likely dose
Aspirin 81 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00110448
NCT00110448Phase 4Completed
CompareCT.gov

Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial

Kumamoto University·interventional·Posted May 10, 2005·Updated Nov 2, 2016

In Brief

A Phase 4 clinical trial evaluating Aspirin and No aspirin for Coronary Disease and 2 related conditions. Completed, enrolled 2,539 participants across 2 sites.

Detailed Summary

The purpose of this study is to determine the effects of low-dose aspirin for the primary prevention of vascular events in patients with type 2 diabetes in Japan.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Disease, Arteriosclerosis, Diabetes Mellitus, Type 2
CountriesJapan
Collaborators--

Timeline

Phase 4CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 10, 2005
Enrollment StartDec 1, 2002
Primary CompletionApr 1, 2008
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 21.1 years ago

Interventions

Aspirindrug

Aspirin 81 mg or 100 mg per day

No aspirindrug

No aspirin use